Macrophage migration inhibitory factor promotes tumor aggressiveness of esophageal squamous cell carcinoma via activation of Akt and inactivation of GSK3β

被引:23
|
作者
Liu, Rui-Min [1 ]
Sun, Dan-Ni [1 ]
Jiao, Ye-Lin [2 ]
Wang, Pan [3 ]
Zhang, Juan [1 ]
Wang, Ming [1 ]
Ma, Jin [1 ]
Sun, Man [2 ]
Gu, Bian-Li [2 ]
Chen, Pan [2 ]
Liu, Ke [2 ]
Ma, Heng [4 ]
Gao, She-Gan [2 ]
Ma, Yuan-Fang [1 ]
Qi, Yi-Jun [2 ]
机构
[1] Henan Univ, Med Coll, Joint Natl Lab Antibody Drug Engn, Kaifeng 475004, Henan, Peoples R China
[2] Henan Univ Sci & Technol, Med Coll, Coll Clin Med, Henan Key Lab Canc Epigenet,Canc Hosp,Affiliated, Luoyang 471003, Peoples R China
[3] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin 300193, Peoples R China
[4] Xinmi Hosp Tradit Chinese Med, Resp Dept, Xinmi 452370, Peoples R China
基金
中国国家自然科学基金;
关键词
Esophageal squamous cell carcinoma; MIF; Cancer progression; Prognosis; GSK3; beta; FACTOR INDUCES ANGIOGENESIS; FACTOR MIF; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; RECEPTOR CD74; IN-VITRO; CANCER; INFLAMMATION; EXPRESSION; GROWTH;
D O I
10.1016/j.canlet.2017.10.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pleiotropic pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF), represents an important link between chronic inflammation and tumorigenesis. Although accumulating evidence demonstrates that MIF overexpression is implicated in the development and progression of multiple cancers, including esophageal squamous cell carcinoma (ESCC), the molecular mechanisms underlying its tumor-promoting roles in ESCC remain unclear. In the present study, we observed that MIF is overexpressed in ESCC and correlated significantly with lymph node metastasis, advanced clinical stage, and poor survival of ESCC. MIF knockdown attenuated the proliferation, migration, and invasion of ESCC cells in vitro and in vivo. Moreover, blockage of MIF expression decreased the activation of the Akt, MEK/ERK, and NF-kappa B pathways and enhanced sensitivity to apoptosis. Meanwhile, repression of MIF expression resulted in activation of glycogen synthase kinase 3 beta (GSK3 beta) and subsequent decrease of active (beta-catenin, as well as its downstream targets including cyclin D1, matrix metalloproteinase (MMP)-7, c-myc, and c-Jun. Collectively, our results provided mechanistic insights into the tumor-promoting role of MIF in ESCC, and suggested that MIF represents a potential therapeutic target for treatment of ESCC. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:289 / 296
页数:8
相关论文
共 50 条
  • [21] T-cadherin promotes vascular smooth muscle cell dedifferentiation via a GSK3β-inactivation dependent mechanism
    Frismantiene, Agne
    Dasen, Boris
    Pfaff, Dennis
    Erne, Paul
    Resink, Therese J.
    Philippova, Maria
    CELLULAR SIGNALLING, 2016, 28 (05) : 516 - 530
  • [22] The pseudogene PTTG3P promotes cell migration and invasion in esophageal squamous cell carcinoma
    Zhang, Zhenhua
    Shi, Zhengyuan
    OPEN MEDICINE, 2019, 14 (01): : 516 - 522
  • [23] CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway
    Jia, Yang
    Xiao, Zhaohua
    Xin Gongsun
    Xin, Zhongwei
    Shang, Bin
    Chen, Gang
    Wang, Zhou
    Jiang, Wenpeng
    ONCOTARGETS AND THERAPY, 2018, 11 : 4221 - 4232
  • [24] GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway
    Xi, Jianbo
    Sun, Yaocheng
    Zhang, Meiting
    Fa, Zhenzhong
    Wan, Yanya
    Min, Zhenyu
    Xu, Hong
    Xu, Chengkai
    Tang, Jianjun
    EXPERIMENTAL CELL RESEARCH, 2019, 381 (01) : 1 - 9
  • [25] PCSK9 promotes tumor cell proliferation and migration by facilitating CCL25 secretion in esophageal squamous cell carcinoma
    Wang, Haijun
    Guo, Qiang
    Wang, Mingbo
    Liu, Changjiang
    Tian, Ziqiang
    ONCOLOGY LETTERS, 2023, 26 (05)
  • [26] Overexpression of ZNF468 promotes esophageal squamous cell carcinoma progression via the AKT/mTOR pathway
    Ye, Luxia
    Pan, Yixiao
    Bao, Jiaqian
    Guo, Yiqing
    Lu, Lingxiao
    Zheng, Jingmin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [27] Increased Expression of Macrophage Migration Inhibitory Factor During Progression to Hypopharyngeal Squamous Cell Carcinoma
    Cludts, Stephanie
    Decaestecker, Christine
    Johnson, Bryon
    Lechien, Jerome
    Leroy, Xavier
    Kindt, Nadege
    Kaltner, Herbert
    Andre, Sabine
    Gabius, Hans-Joachim
    Saussez, Sven
    ANTICANCER RESEARCH, 2010, 30 (09) : 3313 - 3319
  • [28] Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung
    Koh, Hyun Min
    Kim, Dong Chul
    Kim, Yu-min
    Song, Dae Hyun
    THORACIC CANCER, 2019, 10 (12) : 2209 - 2217
  • [29] Macrophage migration inhibitory factor: a potential driver and biomarker for head and neck squamous cell carcinoma
    Wang, Sha-sha
    Cen, Xiao
    Liang, Xin-hua
    Tang, Ya-ling
    ONCOTARGET, 2017, 8 (06) : 10650 - 10661
  • [30] Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy
    Wang, Xiao-Bing
    Jiang, Xing-Ran
    Yu, Xi-Ying
    Wang, Lin
    He, Shun
    Feng, Fei-Yue
    Guo, Li-Ping
    Jiang, Wei
    Lu, Shih-Hsin
    CANCER SCIENCE, 2014, 105 (02): : 176 - 185